Attributable mortality of candidemia - Results from the ECMM Candida III multinational European Observational Cohort Study

[Introduction] Despite antifungal advancements, candidaemia still has a high mortality rate of up to 40%. The ECMM Candida III study in Europe investigated the changing epidemiology and outcomes of candidaemia for better understanding and management of these infections.

Bibliographic Details
Authors: Salmanton-García, Jon, Cornely, Oliver A., Stemler, Jannik, Barać, Aleksandra, Steinmann, Jörg, Siváková, Alena, Akalin, Emin Halis, Arikan-Akdagli, Sevtap, Loughlin, Laura, Toscano, Cristina, Narayanan, Manjusha, Rogers, Benedict, Willinger, Birgit, Akyol, Deniz, Roilides, Emmanuel, Lagrou, Katrien, Mikulska, Malgorzata, Denis, Blandine, Ponscarme, Diane, Scharmann, Urlike, Azap, Alpay, Lockhart, Deborah, Bicanic, Tihana, Kron, Florian, Erben, Nurettin, Rautemaa-Richardson, Riina, Goodman, Anna L., García-Vidal, Carolina, Lass-Flörl, Cornelia, Gangneux, Jean-Pierre, Taramasso, Lucia, Ruiz, Maite, Schick, Yael, Van Wijngaerden, Eric, Milacek, Christopher, Giacobbe, Daniele Roberto, Logan, Clare, Rooney, Emily, Gori, Andrea, Akova, Murat, Bassetti, Matteo, Hoenigl, Martin, Koehler, Philipp
Format: article
Status:Published version
Publication Date:2024
Country:España
Institution:Consejo Superior de Investigaciones Científicas (CSIC)
Repository:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/384570
Online Access:http://hdl.handle.net/10261/384570
https://api.elsevier.com/content/abstract/scopus_id/85199779619
Access Level:Open access
Keyword:Risk factors
Candida
Candidaemia
Epidemiology
Hospitalization
Mortality
Description
Summary:[Introduction] Despite antifungal advancements, candidaemia still has a high mortality rate of up to 40%. The ECMM Candida III study in Europe investigated the changing epidemiology and outcomes of candidaemia for better understanding and management of these infections.

Similar Items